Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

On May 24, 2018, GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow. Under the terms of agreement, the full-cycle manufacturing of finished dosage form will be launched no later than… Continue reading